A First in Human Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of KYN-5356 in Adult, Healthy Subjects
Latest Information Update: 20 Dec 2024
At a glance
- Drugs KYN 5356 (Primary)
- Indications Cognition disorders; Schizophrenia
- Focus Adverse reactions; First in man
- Sponsors Kynexis
Most Recent Events
- 17 Dec 2024 According to a Kynexis media release, company look forward to sharing the full phase 1 results at a scientific conference next year.
- 17 Dec 2024 Results presented in the Kynexis Media Release.
- 04 Dec 2024 Status changed from active, no longer recruiting to completed.